Drug Profile
PF 5105679
Alternative Names: PF-05105679Latest Information Update: 16 Mar 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Analgesics
- Mechanism of Action TRPM8 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 30 Sep 2011 Pfizer completes a phase I trial in Healthy volunteers in Belgium (NCT01393652)
- 23 May 2011 Phase-I clinical trials in Pain in Belgium (unspecified route)